This company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsJounce Therapeutics (JNCE) 주식 개요Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. 자세히 보기JNCE 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성6/6배당0/6위험 분석지난 5년간 매년 수익이 34.3% 감소했습니다.지난 3개월 동안 주가 변동성이 US 시장과 비교했을 때 매우 높았습니다.의미 있는 시가총액이 없습니다($99M)모든 위험 점검 보기JNCE Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.8819.0% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-91m148m2016201920222025202620282031Revenue US$39.7mEarnings US$7.3mAdvancedSet Fair ValueView all narrativesJounce Therapeutics, Inc. 경쟁사Abeona TherapeuticsSymbol: NasdaqCM:ABEOMarket cap: US$312.9mHomology MedicinesSymbol: NasdaqGS:FIXXMarket cap: US$54.3mVaxartSymbol: OTCPK:VXRTMarket cap: US$153.0mCollPlant BiotechnologiesSymbol: NasdaqCM:CLGNMarket cap: US$5.9m가격 이력 및 성과Jounce Therapeutics 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$1.8852주 최고가US$5.4952주 최저가US$0.58베타0.751개월 변동-0.53%3개월 변동55.37%1년 변동-65.76%3년 변동-60.34%5년 변동-88.80%IPO 이후 변동-89.10%최근 뉴스 및 업데이트공시 • May 06+ 1 more updateJounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from NASDAQ Composite IndexJounce Therapeutics, Inc. has been dropped from NASDAQ Composite Index.공시 • May 05+ 1 more updateJounce Therapeutics, Inc. Announces Board ChangesJounce Therapeutics, Inc. announced that at the effective time of the Merger, each of Jigar Raythatha, Luiz A. Diaz, Jr., Barbara Duncan, Robert Iannone, Robert Kamen, Perry Karsen, Richard Murray and Luisa Salter-Cid resigned from the board of directors of the Company.Recent Insider Transactions Derivative • Apr 08President notifies of intention to sell stockRichard Murray intends to sell 52k shares in the next 90 days after lodging an Intent To Sell Form on the 3rd of April. If the sale is conducted around the recent share price of US$1.85, it would amount to US$95k. For the year to December 2016, Richard's total compensation was 18% salary and 82% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2022, Richard's direct individual holding has decreased from 273.08k shares to 142.17k. Company insiders have collectively sold US$95k more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • Mar 11Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: US$0.98 loss per share (improved from US$1.82 loss in FY 2021). Revenue: US$82.0m (up 205% from FY 2021). Net loss: US$50.9m (loss narrowed 44% from FY 2021). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 51%. Revenue is expected to decline by 180% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the US are expected to grow by 14%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 29 percentage points per year, which is a significant difference in performance.Major Estimate Revision • Feb 24Consensus revenue estimates increase by 76%The consensus outlook for revenues in fiscal year 2022 has improved. 2022 revenue forecast increased from US$18.7m to US$32.8m. Forecast losses expected to reduce from -US$2.17 to -US$1.90 per share. Biotechs industry in the US expected to see average net income decline 79% next year. Consensus price target of US$6.67 unchanged from last update. Share price rose 3.6% to US$1.14 over the past week.Price Target Changed • Feb 24Price target increased by 8.9% to US$6.75Up from US$6.20, the current price target is an average from 4 analysts. New target price is 514% above last closing price of US$1.10. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$1.90 next year compared to a net loss per share of US$1.82 last year.더 많은 업데이트 보기Recent updates공시 • May 06+ 1 more updateJounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from NASDAQ Composite IndexJounce Therapeutics, Inc. has been dropped from NASDAQ Composite Index.공시 • May 05+ 1 more updateJounce Therapeutics, Inc. Announces Board ChangesJounce Therapeutics, Inc. announced that at the effective time of the Merger, each of Jigar Raythatha, Luiz A. Diaz, Jr., Barbara Duncan, Robert Iannone, Robert Kamen, Perry Karsen, Richard Murray and Luisa Salter-Cid resigned from the board of directors of the Company.Recent Insider Transactions Derivative • Apr 08President notifies of intention to sell stockRichard Murray intends to sell 52k shares in the next 90 days after lodging an Intent To Sell Form on the 3rd of April. If the sale is conducted around the recent share price of US$1.85, it would amount to US$95k. For the year to December 2016, Richard's total compensation was 18% salary and 82% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2022, Richard's direct individual holding has decreased from 273.08k shares to 142.17k. Company insiders have collectively sold US$95k more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • Mar 11Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: US$0.98 loss per share (improved from US$1.82 loss in FY 2021). Revenue: US$82.0m (up 205% from FY 2021). Net loss: US$50.9m (loss narrowed 44% from FY 2021). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 51%. Revenue is expected to decline by 180% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the US are expected to grow by 14%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 29 percentage points per year, which is a significant difference in performance.Major Estimate Revision • Feb 24Consensus revenue estimates increase by 76%The consensus outlook for revenues in fiscal year 2022 has improved. 2022 revenue forecast increased from US$18.7m to US$32.8m. Forecast losses expected to reduce from -US$2.17 to -US$1.90 per share. Biotechs industry in the US expected to see average net income decline 79% next year. Consensus price target of US$6.67 unchanged from last update. Share price rose 3.6% to US$1.14 over the past week.Price Target Changed • Feb 24Price target increased by 8.9% to US$6.75Up from US$6.20, the current price target is an average from 4 analysts. New target price is 514% above last closing price of US$1.10. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$1.90 next year compared to a net loss per share of US$1.82 last year.Recent Insider Transactions Derivative • Jan 13President notifies of intention to sell stockRichard Murray intends to sell 45k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of January. If the sale is conducted around the recent share price of US$1.14, it would amount to US$51k. For the year to December 2016, Richard's total compensation was 18% salary and 82% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Richard has owned 273.08k shares directly. Company insiders have collectively sold US$95k more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Jan 13President recently sold US$50k worth of stockOn the 10th of January, Richard Murray sold around 45k shares on-market at roughly US$1.11 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.공시 • Jan 06Jounce Therapeutics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement for Continued Inclusion on the Nasdaq Global Select MarketOn December 29, 2022, Jounce Therapeutics, Inc. ("the Company"), received a deficiency letter from the Listing Qualifications Department ("the Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days, the bid price for the Company's common stock, par value $0.001 per share (the Common Stock"), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) ("the Bid Price Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the Compliance Period Rule"), the Company has been provided a period of 180 calendar days, or until June 27, 2023 (the Compliance Date"), to regain compliance with the Bid Price Requirement. If, at any time before the Compliance Date, the bid price for the Common Stock closes at $1.00 or more for a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it has regained compliance with the Bid Price Requirement, unless the Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date, the Company may be eligible to extend the compliance period for an additional 180 calendar days. To qualify, the Company would need to transfer the listing of the Common Stock to Nasdaq Capital Market, provided that it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards, with the exception of the Bid Price Requirement. To effect such a transfer, the Company would also need to pay an application fee to Nasdaq and will need to provide written notice to the Staff of its intention to cure the deficiency during the additional compliance period by effecting a reverse stock split, if necessary. As part of its review process, the Staff will make a determination of whether it believes the Company will be able to cure this deficiency. Should the Staff conclude that the Company will not be able to cure the deficiency, or should the Company determine not to submit an application for transfer to the Nasdaq Capital Market or notify the Staff of its intention to cure the deficiency, the Staff will provide written notification to the Company that the Common Stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Listing Qualifications Panel (the Panel"). However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by the Staff to the Panel, such appeal would be successful. The Company intends to monitor the closing bid price of the Common Stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement, which could include seeking to effect a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement.분석 기사 • Jan 04We're A Little Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Major Estimate Revision • Jan 03Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$7.50m to US$6.00m. EPS estimate unchanged at -US$2.40 per share. Biotechs industry in the US expected to see average net income decline 82% next year. Consensus price target down from US$6.20 to US$6.00. Share price rose 51% to US$1.11 over the past week.Major Estimate Revision • Nov 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$9.17m to US$6.00m. EPS estimate increased from -US$2.43 to -US$2.35 per share. Biotechs industry in the US expected to see average net income decline 94% next year. Consensus price target down from US$11.00 to US$8.20. Share price fell 51% to US$0.98 over the past week.Price Target Changed • Nov 16Price target decreased to US$8.20Down from US$11.00, the current price target is an average from 5 analysts. New target price is 712% above last closing price of US$1.01. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$2.40 next year compared to a net loss per share of US$1.82 last year.Major Estimate Revision • Nov 12Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$9.17m to US$3.75m. EPS estimate increased from -US$2.43 to -US$2.39 per share. Biotechs industry in the US expected to see average net income decline 62% next year. Consensus price target down from US$11.00 to US$8.20. Share price fell 40% to US$1.18 over the past week.분석 기사 • Sep 20Here's Why We're Watching Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...Price Target Changed • Aug 06Price target decreased to US$12.83Down from US$13.83, the current price target is an average from 7 analysts. New target price is 208% above last closing price of US$4.16. Stock is down 20% over the past year. The company is forecast to post a net loss per share of US$2.37 next year compared to a net loss per share of US$1.82 last year.분석 기사 • Jun 16Here's Why We're A Bit Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...Price Target Changed • May 23Price target decreased to US$14.00Down from US$15.57, the current price target is an average from 9 analysts. New target price is 201% above last closing price of US$4.65. Stock is down 42% over the past year. The company is forecast to post a net loss per share of US$2.44 next year compared to a net loss per share of US$1.82 last year.Major Estimate Revision • May 12Consensus revenue estimates fall by 87%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$21.3m to US$2.86m. Forecast losses increased from -US$2.05 to -US$2.58 per share. Biotechs industry in the US expected to see average net income decline 44% next year. Consensus price target down from US$16.75 to US$16.29. Share price fell 18% to US$4.29 over the past week.Reported Earnings • May 06First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.72 loss per share (down from US$0.58 loss in 1Q 2021). Revenue: US$0 (down 100% from 1Q 2021). Net loss: US$37.4m (loss widened 41% from 1Q 2021). Profit margin: (up from net loss in 1Q 2021). The move to profitability was primarily driven by lower revenue. Revenue missed analyst estimates by 100%. Earnings per share (EPS) also missed analyst estimates by 25%. Over the next year, revenue is expected to shrink by 61% compared to a 41% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Price Target Changed • Apr 27Price target increased to US$15.57Up from US$14.50, the current price target is an average from 8 analysts. New target price is 156% above last closing price of US$6.08. Stock is down 37% over the past year. The company is forecast to post a net loss per share of US$2.05 next year compared to a net loss per share of US$1.82 last year.Price Target Changed • Mar 17Price target increased to US$15.57Up from US$14.50, the current price target is an average from 8 analysts. New target price is 113% above last closing price of US$7.32. Stock is down 35% over the past year. The company is forecast to post a net loss per share of US$2.05 next year compared to a net loss per share of US$1.82 last year.Major Estimate Revision • Mar 12Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$19.1m to US$21.3m. EPS estimate unchanged at -US$2.05. Biotechs industry in the US expected to see average net income decline 38% next year. Consensus price target of US$15.33 unchanged from last update. Share price rose 7.8% to US$7.22 over the past week.Reported Earnings • Mar 04Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$1.82 loss per share (down from US$1.24 loss in FY 2020). Revenue: US$26.9m (down 57% from FY 2020). Net loss: US$90.9m (loss widened 107% from FY 2020). Products in clinical trials Phase I: 1 Phase II: 3 Revenue missed analyst estimates by 31%. Earnings per share (EPS) exceeded analyst estimates by 16%. Over the next year, revenue is expected to shrink by 96% compared to a 71% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.분석 기사 • Feb 23We Think Jounce Therapeutics (NASDAQ:JNCE) Can Easily Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Recent Insider Transactions • Jan 14President recently sold US$257k worth of stockOn the 10th of January, Richard Murray sold around 37k shares on-market at roughly US$6.88 per share. This was the largest sale by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.Recent Insider Transactions Derivative • Jan 11President notifies of intention to sell stockRichard Murray intends to sell 34k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of January. If the sale is conducted around the recent share price of US$8.35, it would amount to US$281k. For the year to December 2020, Richard's total compensation was 28% salary and 72% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2021, Richard's direct individual holding has decreased from 222.87k shares to 91.53k. Company insiders have collectively sold US$1.6m more than they bought, via options and on-market transactions in the last 12 months.Seeking Alpha • Dec 16Jounce Therapeutics: A Favorable Risk-Reward Ahead Of Critical 2022 CatalystsJounce is making an attempt to renovate how we treat cancer by developing novel immunotherapies that could expand these treatments to new patients and tumor types. The company’s platform and R&D capabilities are impressive. If all goes well, Jounce could have several blockbuster drugs in their pipeline. Jounce has an attractive license deal with Gilead, which has provided some cash with milestones and royalties. The company expects to report data from their INNATE study and their SELECT study in 2022. If the data is promising, the market should react positively as they recognize the prospect JNCE provides.Price Target Changed • Sep 14Price target decreased to US$14.50Down from US$16.03, the current price target is an average from 8 analysts. New target price is 100% above last closing price of US$7.24. Stock is down 34% over the past year.분석 기사 • Aug 07News Flash: Analysts Just Made A Dazzling Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) ForecastsCelebrations may be in order for Jounce Therapeutics, Inc. ( NASDAQ:JNCE ) shareholders, with the analysts delivering a...Major Estimate Revision • Aug 06Consensus revenue estimates increase to US$47.4mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$25.8m to US$47.4m. Forecast losses expected to reduce from -US$1.80 to -US$1.49 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$15.43 unchanged from last update. Share price rose 3.4% to US$5.21 over the past week.Seeking Alpha • Jul 13Jounce Therapeutics: An Under The Radar And Undervalued BiotechJounce is a clinical stage biotech company that is attempting to transform the treatment of cancer by developing novel immunotherapies. The science is promising, but still in its early stages. A license deal with Gilead has provided credibility to Jounce's platform and helped to strengthen its cash position. Currently at 1.13x book value, shares of Jounce look cheap and present an investment opportunity with a favorable risk-reward profile.Major Estimate Revision • Jun 17Consensus revenue estimates increase to US$25.8mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$22.2m to US$25.8m. Forecast losses expected to reduce from -US$1.93 to -US$1.87 per share. Biotechs industry in the US expected to see average net income decline 5.1% next year. Consensus price target of US$16.03 unchanged from last update. Share price was steady at US$7.38 over the past week.분석 기사 • Jun 16Need To Know: Analysts Are Much More Bullish On Jounce Therapeutics, Inc. (NASDAQ:JNCE) RevenuesCelebrations may be in order for Jounce Therapeutics, Inc. ( NASDAQ:JNCE ) shareholders, with the analysts delivering a...분석 기사 • Jun 12Shareholders May Not Be So Generous With Jounce Therapeutics, Inc.'s (NASDAQ:JNCE) CEO Compensation And Here's WhyAs many shareholders of Jounce Therapeutics, Inc. ( NASDAQ:JNCE ) will be aware, they have not made a gain on their...Major Estimate Revision • May 11Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$54.5m to US$15.6m. EPS estimate increased from -US$1.98 to -US$1.93 per share. Biotechs industry in the US expected to see average net income decline 8.7% next year. Consensus price target of US$16.00 unchanged from last update. Share price fell 20% to US$7.46 over the past week.분석 기사 • May 03We're Hopeful That Jounce Therapeutics (NASDAQ:JNCE) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although...Recent Insider Transactions Derivative • Apr 02Chief Medical Officer exercised options and sold US$82k worth of stockOn the 31st of March, Elizabeth Trehu exercised 14k options at a strike price of around US$4.02 and sold these shares for an average price of US$10.09 per share. This trade did not impact their existing holding. Since June 2020, Elizabeth's direct individual holding has increased from 34.53k shares to 93.59k. Company insiders have collectively sold US$1.9m more than they bought, via options and on-market transactions in the last 12 months.Is New 90 Day High Low • Mar 12New 90-day high: US$13.87The company is up 109% from its price of US$6.65 on 11 December 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 1.0% over the same period.Major Estimate Revision • Mar 04Analysts increase revenue estimates to US$54.5mThe 2021 consensus revenue estimate increased from US$43.2m. Earning per share (EPS) estimate also saw an improvement, with analysts raising their estimates from -US$1.62 to -US$1.43 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 3.5% next year. The consensus price target increased from US$9.88 to US$15.00. Share price is up 11% to US$12.22 over the past week.분석 기사 • Mar 02Jounce Therapeutics (NASDAQ:JNCE) Shareholders Have Enjoyed An Impressive 163% Share Price GainUnfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right business to buy shares...분석 기사 • Mar 02News Flash: Analysts Just Made A Sizeable Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) ForecastsJounce Therapeutics, Inc. ( NASDAQ:JNCE ) shareholders will have a reason to smile today, with the analysts making...Reported Earnings • Feb 27Full year 2020 earnings released: US$1.24 loss per share (vs US$1.72 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: US$62.3m (down 58% from FY 2019). Net loss: US$43.8m (down 177% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Feb 27Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 85%. Earnings per share (EPS) missed analyst estimates by 38%. Over the next year, revenue is forecast to grow 66%, compared to a 1,389% growth forecast for the Biotechs industry in the US.Is New 90 Day High Low • Feb 06New 90-day high: US$13.47The company is up 99% from its price of US$6.76 on 06 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 24% over the same period.Recent Insider Transactions Derivative • Jan 22President notifies of intention to sell stockRichard Murray intends to sell roughly 70.00k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of January. If the sale is conducted around the recent share price of US$7.74, it would amount to US$542k. For the year to December 2019, Richard's total compensation was 37% salary and 63% non-salary (Indicating these sales could comprise a meaningful part of their income for the year). Since March 2020, Richard's direct individual holding has decreased from 162.37k shares to 140.37k. Company insiders have collectively sold US$360k more than they bought, via options and on-market transactions in the last 12 months.Is New 90 Day High Low • Jan 21New 90-day high: US$11.35The company is up 19% from its price of US$9.55 on 22 October 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 27% over the same period.Recent Insider Transactions • Jan 13President recently sold US$152k worth of stockOn the 8th of January, Richard Murray sold around 22k shares on-market at roughly US$6.89 per share. This was the largest sale by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.분석 기사 • Jan 13Have Insiders Sold Jounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Recently?Anyone interested in Jounce Therapeutics, Inc. ( NASDAQ:JNCE ) should probably be aware that the President, Richard...Recent Insider Transactions Derivative • Jan 09President notifies of intention to sell stockRichard Murray intends to sell roughly 23.38k shares in the next 90 days after lodging an Intent To Sell Form on the 7th of January. If the sale is conducted around the recent share price of US$7.00, it would amount to US$164k. For the year to December 2019, Richard's total compensation was 37% salary and 63% non-salary (Indicating these sales could comprise a meaningful part of their income for the year). Since March 2020, Richard's direct individual holding has decreased from 162.37k shares to 45.69k. Company insiders have collectively sold US$89k more than they bought, via options and on-market transactions in the last 12 months.Is New 90 Day High Low • Dec 24New 90-day low: US$6.60The company is down 16% from its price of US$7.89 on 24 September 2020. The American market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.분석 기사 • Dec 15A Look At Jounce Therapeutics' (NASDAQ:JNCE) CEO RemunerationThis article will reflect on the compensation paid to Rich Murray who has served as CEO of Jounce Therapeutics, Inc...Analyst Estimate Surprise Post Earnings • Nov 10Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 64%.Analyst Estimate Surprise Post Earnings • Nov 08Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 64%.Major Estimate Revision • Nov 04Analysts increase revenue estimates to US$21.9mThe 2020 consensus revenue estimate increased from US$4.17m. Earning per share (EPS) estimate also saw an improvement, with analysts raising their estimates from -US$3.09 to -US$2.62 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 7.4% next year. The consensus price target of US$13.83 was unchanged from the last update. Share price is down by 22% to US$7.02 over the past week.Valuation Update With 7 Day Price Move • Nov 03Market pulls back on stock over the past weekAfter last week's 24% share price decline to US$6.82, the stock is trading at a trailing P/E ratio of 10.5x, down from the previous P/E ratio of 13.9x. This compares to an average P/E of 29x in the Biotechs industry in the US. Total return to shareholders over the past three years is a loss of 54%.Price Target Changed • Sep 19Price target raised to US$14.30Up from US$10.63, the current price target is an average from 7 analysts. The new target price is 45% above the current share price of US$9.85. As of last close, the stock is up 191% over the past year.주주 수익률JNCEUS BiotechsUS 시장7D-2.6%1.0%1.3%1Y-65.8%34.2%27.7%전체 주주 수익률 보기수익률 대 산업: JNCE은 지난 1년 동안 34.2%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.수익률 대 시장: JNCE은 지난 1년 동안 27.7%를 기록한 US 시장보다 저조한 성과를 냈습니다.주가 변동성Is JNCE's price volatile compared to industry and market?JNCE volatilityJNCE Average Weekly Movement15.4%Biotechs Industry Average Movement10.9%Market Average Movement7.2%10% most volatile stocks in US Market16.6%10% least volatile stocks in US Market3.0%안정적인 주가: JNCE의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: JNCE의 주간 변동성(15%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트2012141n/ajouncetx.com더 보기Jounce Therapeutics, Inc. 기초 지표 요약Jounce Therapeutics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?JNCE 기초 통계시가총액US$98.96m순이익 (TTM)-US$50.92m매출 (TTM)US$82.00m1.2x주가매출비율(P/S)-1.9x주가수익비율(P/E)JNCE는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표JNCE 손익계산서 (TTM)매출US$82.00m매출원가US$54.80m총이익US$27.20m기타 비용US$78.12m순이익-US$50.92m최근 보고된 실적Dec 31, 2022다음 실적 발표일해당 없음주당순이익(EPS)-0.97총이익률33.17%순이익률-62.10%부채/자본 비율0%JNCE의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/05/06 07:20종가2023/05/03 00:00수익2022/12/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Jounce Therapeutics, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Colleen KusyBairdSwayampakula RamakanthH.C. Wainwright & Co.Cory KasimovJ.P. Morgan6명의 분석가 더 보기
공시 • May 06+ 1 more updateJounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from NASDAQ Composite IndexJounce Therapeutics, Inc. has been dropped from NASDAQ Composite Index.
공시 • May 05+ 1 more updateJounce Therapeutics, Inc. Announces Board ChangesJounce Therapeutics, Inc. announced that at the effective time of the Merger, each of Jigar Raythatha, Luiz A. Diaz, Jr., Barbara Duncan, Robert Iannone, Robert Kamen, Perry Karsen, Richard Murray and Luisa Salter-Cid resigned from the board of directors of the Company.
Recent Insider Transactions Derivative • Apr 08President notifies of intention to sell stockRichard Murray intends to sell 52k shares in the next 90 days after lodging an Intent To Sell Form on the 3rd of April. If the sale is conducted around the recent share price of US$1.85, it would amount to US$95k. For the year to December 2016, Richard's total compensation was 18% salary and 82% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2022, Richard's direct individual holding has decreased from 273.08k shares to 142.17k. Company insiders have collectively sold US$95k more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • Mar 11Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: US$0.98 loss per share (improved from US$1.82 loss in FY 2021). Revenue: US$82.0m (up 205% from FY 2021). Net loss: US$50.9m (loss narrowed 44% from FY 2021). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 51%. Revenue is expected to decline by 180% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the US are expected to grow by 14%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 29 percentage points per year, which is a significant difference in performance.
Major Estimate Revision • Feb 24Consensus revenue estimates increase by 76%The consensus outlook for revenues in fiscal year 2022 has improved. 2022 revenue forecast increased from US$18.7m to US$32.8m. Forecast losses expected to reduce from -US$2.17 to -US$1.90 per share. Biotechs industry in the US expected to see average net income decline 79% next year. Consensus price target of US$6.67 unchanged from last update. Share price rose 3.6% to US$1.14 over the past week.
Price Target Changed • Feb 24Price target increased by 8.9% to US$6.75Up from US$6.20, the current price target is an average from 4 analysts. New target price is 514% above last closing price of US$1.10. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$1.90 next year compared to a net loss per share of US$1.82 last year.
공시 • May 06+ 1 more updateJounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from NASDAQ Composite IndexJounce Therapeutics, Inc. has been dropped from NASDAQ Composite Index.
공시 • May 05+ 1 more updateJounce Therapeutics, Inc. Announces Board ChangesJounce Therapeutics, Inc. announced that at the effective time of the Merger, each of Jigar Raythatha, Luiz A. Diaz, Jr., Barbara Duncan, Robert Iannone, Robert Kamen, Perry Karsen, Richard Murray and Luisa Salter-Cid resigned from the board of directors of the Company.
Recent Insider Transactions Derivative • Apr 08President notifies of intention to sell stockRichard Murray intends to sell 52k shares in the next 90 days after lodging an Intent To Sell Form on the 3rd of April. If the sale is conducted around the recent share price of US$1.85, it would amount to US$95k. For the year to December 2016, Richard's total compensation was 18% salary and 82% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2022, Richard's direct individual holding has decreased from 273.08k shares to 142.17k. Company insiders have collectively sold US$95k more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • Mar 11Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: US$0.98 loss per share (improved from US$1.82 loss in FY 2021). Revenue: US$82.0m (up 205% from FY 2021). Net loss: US$50.9m (loss narrowed 44% from FY 2021). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 51%. Revenue is expected to decline by 180% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the US are expected to grow by 14%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 29 percentage points per year, which is a significant difference in performance.
Major Estimate Revision • Feb 24Consensus revenue estimates increase by 76%The consensus outlook for revenues in fiscal year 2022 has improved. 2022 revenue forecast increased from US$18.7m to US$32.8m. Forecast losses expected to reduce from -US$2.17 to -US$1.90 per share. Biotechs industry in the US expected to see average net income decline 79% next year. Consensus price target of US$6.67 unchanged from last update. Share price rose 3.6% to US$1.14 over the past week.
Price Target Changed • Feb 24Price target increased by 8.9% to US$6.75Up from US$6.20, the current price target is an average from 4 analysts. New target price is 514% above last closing price of US$1.10. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$1.90 next year compared to a net loss per share of US$1.82 last year.
Recent Insider Transactions Derivative • Jan 13President notifies of intention to sell stockRichard Murray intends to sell 45k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of January. If the sale is conducted around the recent share price of US$1.14, it would amount to US$51k. For the year to December 2016, Richard's total compensation was 18% salary and 82% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Richard has owned 273.08k shares directly. Company insiders have collectively sold US$95k more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Jan 13President recently sold US$50k worth of stockOn the 10th of January, Richard Murray sold around 45k shares on-market at roughly US$1.11 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.
공시 • Jan 06Jounce Therapeutics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement for Continued Inclusion on the Nasdaq Global Select MarketOn December 29, 2022, Jounce Therapeutics, Inc. ("the Company"), received a deficiency letter from the Listing Qualifications Department ("the Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days, the bid price for the Company's common stock, par value $0.001 per share (the Common Stock"), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) ("the Bid Price Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the Compliance Period Rule"), the Company has been provided a period of 180 calendar days, or until June 27, 2023 (the Compliance Date"), to regain compliance with the Bid Price Requirement. If, at any time before the Compliance Date, the bid price for the Common Stock closes at $1.00 or more for a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it has regained compliance with the Bid Price Requirement, unless the Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date, the Company may be eligible to extend the compliance period for an additional 180 calendar days. To qualify, the Company would need to transfer the listing of the Common Stock to Nasdaq Capital Market, provided that it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards, with the exception of the Bid Price Requirement. To effect such a transfer, the Company would also need to pay an application fee to Nasdaq and will need to provide written notice to the Staff of its intention to cure the deficiency during the additional compliance period by effecting a reverse stock split, if necessary. As part of its review process, the Staff will make a determination of whether it believes the Company will be able to cure this deficiency. Should the Staff conclude that the Company will not be able to cure the deficiency, or should the Company determine not to submit an application for transfer to the Nasdaq Capital Market or notify the Staff of its intention to cure the deficiency, the Staff will provide written notification to the Company that the Common Stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Listing Qualifications Panel (the Panel"). However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by the Staff to the Panel, such appeal would be successful. The Company intends to monitor the closing bid price of the Common Stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement, which could include seeking to effect a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement.
분석 기사 • Jan 04We're A Little Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Major Estimate Revision • Jan 03Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$7.50m to US$6.00m. EPS estimate unchanged at -US$2.40 per share. Biotechs industry in the US expected to see average net income decline 82% next year. Consensus price target down from US$6.20 to US$6.00. Share price rose 51% to US$1.11 over the past week.
Major Estimate Revision • Nov 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$9.17m to US$6.00m. EPS estimate increased from -US$2.43 to -US$2.35 per share. Biotechs industry in the US expected to see average net income decline 94% next year. Consensus price target down from US$11.00 to US$8.20. Share price fell 51% to US$0.98 over the past week.
Price Target Changed • Nov 16Price target decreased to US$8.20Down from US$11.00, the current price target is an average from 5 analysts. New target price is 712% above last closing price of US$1.01. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$2.40 next year compared to a net loss per share of US$1.82 last year.
Major Estimate Revision • Nov 12Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$9.17m to US$3.75m. EPS estimate increased from -US$2.43 to -US$2.39 per share. Biotechs industry in the US expected to see average net income decline 62% next year. Consensus price target down from US$11.00 to US$8.20. Share price fell 40% to US$1.18 over the past week.
분석 기사 • Sep 20Here's Why We're Watching Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Price Target Changed • Aug 06Price target decreased to US$12.83Down from US$13.83, the current price target is an average from 7 analysts. New target price is 208% above last closing price of US$4.16. Stock is down 20% over the past year. The company is forecast to post a net loss per share of US$2.37 next year compared to a net loss per share of US$1.82 last year.
분석 기사 • Jun 16Here's Why We're A Bit Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Price Target Changed • May 23Price target decreased to US$14.00Down from US$15.57, the current price target is an average from 9 analysts. New target price is 201% above last closing price of US$4.65. Stock is down 42% over the past year. The company is forecast to post a net loss per share of US$2.44 next year compared to a net loss per share of US$1.82 last year.
Major Estimate Revision • May 12Consensus revenue estimates fall by 87%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$21.3m to US$2.86m. Forecast losses increased from -US$2.05 to -US$2.58 per share. Biotechs industry in the US expected to see average net income decline 44% next year. Consensus price target down from US$16.75 to US$16.29. Share price fell 18% to US$4.29 over the past week.
Reported Earnings • May 06First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.72 loss per share (down from US$0.58 loss in 1Q 2021). Revenue: US$0 (down 100% from 1Q 2021). Net loss: US$37.4m (loss widened 41% from 1Q 2021). Profit margin: (up from net loss in 1Q 2021). The move to profitability was primarily driven by lower revenue. Revenue missed analyst estimates by 100%. Earnings per share (EPS) also missed analyst estimates by 25%. Over the next year, revenue is expected to shrink by 61% compared to a 41% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Price Target Changed • Apr 27Price target increased to US$15.57Up from US$14.50, the current price target is an average from 8 analysts. New target price is 156% above last closing price of US$6.08. Stock is down 37% over the past year. The company is forecast to post a net loss per share of US$2.05 next year compared to a net loss per share of US$1.82 last year.
Price Target Changed • Mar 17Price target increased to US$15.57Up from US$14.50, the current price target is an average from 8 analysts. New target price is 113% above last closing price of US$7.32. Stock is down 35% over the past year. The company is forecast to post a net loss per share of US$2.05 next year compared to a net loss per share of US$1.82 last year.
Major Estimate Revision • Mar 12Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$19.1m to US$21.3m. EPS estimate unchanged at -US$2.05. Biotechs industry in the US expected to see average net income decline 38% next year. Consensus price target of US$15.33 unchanged from last update. Share price rose 7.8% to US$7.22 over the past week.
Reported Earnings • Mar 04Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$1.82 loss per share (down from US$1.24 loss in FY 2020). Revenue: US$26.9m (down 57% from FY 2020). Net loss: US$90.9m (loss widened 107% from FY 2020). Products in clinical trials Phase I: 1 Phase II: 3 Revenue missed analyst estimates by 31%. Earnings per share (EPS) exceeded analyst estimates by 16%. Over the next year, revenue is expected to shrink by 96% compared to a 71% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
분석 기사 • Feb 23We Think Jounce Therapeutics (NASDAQ:JNCE) Can Easily Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Recent Insider Transactions • Jan 14President recently sold US$257k worth of stockOn the 10th of January, Richard Murray sold around 37k shares on-market at roughly US$6.88 per share. This was the largest sale by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.
Recent Insider Transactions Derivative • Jan 11President notifies of intention to sell stockRichard Murray intends to sell 34k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of January. If the sale is conducted around the recent share price of US$8.35, it would amount to US$281k. For the year to December 2020, Richard's total compensation was 28% salary and 72% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2021, Richard's direct individual holding has decreased from 222.87k shares to 91.53k. Company insiders have collectively sold US$1.6m more than they bought, via options and on-market transactions in the last 12 months.
Seeking Alpha • Dec 16Jounce Therapeutics: A Favorable Risk-Reward Ahead Of Critical 2022 CatalystsJounce is making an attempt to renovate how we treat cancer by developing novel immunotherapies that could expand these treatments to new patients and tumor types. The company’s platform and R&D capabilities are impressive. If all goes well, Jounce could have several blockbuster drugs in their pipeline. Jounce has an attractive license deal with Gilead, which has provided some cash with milestones and royalties. The company expects to report data from their INNATE study and their SELECT study in 2022. If the data is promising, the market should react positively as they recognize the prospect JNCE provides.
Price Target Changed • Sep 14Price target decreased to US$14.50Down from US$16.03, the current price target is an average from 8 analysts. New target price is 100% above last closing price of US$7.24. Stock is down 34% over the past year.
분석 기사 • Aug 07News Flash: Analysts Just Made A Dazzling Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) ForecastsCelebrations may be in order for Jounce Therapeutics, Inc. ( NASDAQ:JNCE ) shareholders, with the analysts delivering a...
Major Estimate Revision • Aug 06Consensus revenue estimates increase to US$47.4mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$25.8m to US$47.4m. Forecast losses expected to reduce from -US$1.80 to -US$1.49 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$15.43 unchanged from last update. Share price rose 3.4% to US$5.21 over the past week.
Seeking Alpha • Jul 13Jounce Therapeutics: An Under The Radar And Undervalued BiotechJounce is a clinical stage biotech company that is attempting to transform the treatment of cancer by developing novel immunotherapies. The science is promising, but still in its early stages. A license deal with Gilead has provided credibility to Jounce's platform and helped to strengthen its cash position. Currently at 1.13x book value, shares of Jounce look cheap and present an investment opportunity with a favorable risk-reward profile.
Major Estimate Revision • Jun 17Consensus revenue estimates increase to US$25.8mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$22.2m to US$25.8m. Forecast losses expected to reduce from -US$1.93 to -US$1.87 per share. Biotechs industry in the US expected to see average net income decline 5.1% next year. Consensus price target of US$16.03 unchanged from last update. Share price was steady at US$7.38 over the past week.
분석 기사 • Jun 16Need To Know: Analysts Are Much More Bullish On Jounce Therapeutics, Inc. (NASDAQ:JNCE) RevenuesCelebrations may be in order for Jounce Therapeutics, Inc. ( NASDAQ:JNCE ) shareholders, with the analysts delivering a...
분석 기사 • Jun 12Shareholders May Not Be So Generous With Jounce Therapeutics, Inc.'s (NASDAQ:JNCE) CEO Compensation And Here's WhyAs many shareholders of Jounce Therapeutics, Inc. ( NASDAQ:JNCE ) will be aware, they have not made a gain on their...
Major Estimate Revision • May 11Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$54.5m to US$15.6m. EPS estimate increased from -US$1.98 to -US$1.93 per share. Biotechs industry in the US expected to see average net income decline 8.7% next year. Consensus price target of US$16.00 unchanged from last update. Share price fell 20% to US$7.46 over the past week.
분석 기사 • May 03We're Hopeful That Jounce Therapeutics (NASDAQ:JNCE) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Recent Insider Transactions Derivative • Apr 02Chief Medical Officer exercised options and sold US$82k worth of stockOn the 31st of March, Elizabeth Trehu exercised 14k options at a strike price of around US$4.02 and sold these shares for an average price of US$10.09 per share. This trade did not impact their existing holding. Since June 2020, Elizabeth's direct individual holding has increased from 34.53k shares to 93.59k. Company insiders have collectively sold US$1.9m more than they bought, via options and on-market transactions in the last 12 months.
Is New 90 Day High Low • Mar 12New 90-day high: US$13.87The company is up 109% from its price of US$6.65 on 11 December 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 1.0% over the same period.
Major Estimate Revision • Mar 04Analysts increase revenue estimates to US$54.5mThe 2021 consensus revenue estimate increased from US$43.2m. Earning per share (EPS) estimate also saw an improvement, with analysts raising their estimates from -US$1.62 to -US$1.43 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 3.5% next year. The consensus price target increased from US$9.88 to US$15.00. Share price is up 11% to US$12.22 over the past week.
분석 기사 • Mar 02Jounce Therapeutics (NASDAQ:JNCE) Shareholders Have Enjoyed An Impressive 163% Share Price GainUnfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right business to buy shares...
분석 기사 • Mar 02News Flash: Analysts Just Made A Sizeable Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) ForecastsJounce Therapeutics, Inc. ( NASDAQ:JNCE ) shareholders will have a reason to smile today, with the analysts making...
Reported Earnings • Feb 27Full year 2020 earnings released: US$1.24 loss per share (vs US$1.72 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: US$62.3m (down 58% from FY 2019). Net loss: US$43.8m (down 177% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Feb 27Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 85%. Earnings per share (EPS) missed analyst estimates by 38%. Over the next year, revenue is forecast to grow 66%, compared to a 1,389% growth forecast for the Biotechs industry in the US.
Is New 90 Day High Low • Feb 06New 90-day high: US$13.47The company is up 99% from its price of US$6.76 on 06 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 24% over the same period.
Recent Insider Transactions Derivative • Jan 22President notifies of intention to sell stockRichard Murray intends to sell roughly 70.00k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of January. If the sale is conducted around the recent share price of US$7.74, it would amount to US$542k. For the year to December 2019, Richard's total compensation was 37% salary and 63% non-salary (Indicating these sales could comprise a meaningful part of their income for the year). Since March 2020, Richard's direct individual holding has decreased from 162.37k shares to 140.37k. Company insiders have collectively sold US$360k more than they bought, via options and on-market transactions in the last 12 months.
Is New 90 Day High Low • Jan 21New 90-day high: US$11.35The company is up 19% from its price of US$9.55 on 22 October 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 27% over the same period.
Recent Insider Transactions • Jan 13President recently sold US$152k worth of stockOn the 8th of January, Richard Murray sold around 22k shares on-market at roughly US$6.89 per share. This was the largest sale by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.
분석 기사 • Jan 13Have Insiders Sold Jounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Recently?Anyone interested in Jounce Therapeutics, Inc. ( NASDAQ:JNCE ) should probably be aware that the President, Richard...
Recent Insider Transactions Derivative • Jan 09President notifies of intention to sell stockRichard Murray intends to sell roughly 23.38k shares in the next 90 days after lodging an Intent To Sell Form on the 7th of January. If the sale is conducted around the recent share price of US$7.00, it would amount to US$164k. For the year to December 2019, Richard's total compensation was 37% salary and 63% non-salary (Indicating these sales could comprise a meaningful part of their income for the year). Since March 2020, Richard's direct individual holding has decreased from 162.37k shares to 45.69k. Company insiders have collectively sold US$89k more than they bought, via options and on-market transactions in the last 12 months.
Is New 90 Day High Low • Dec 24New 90-day low: US$6.60The company is down 16% from its price of US$7.89 on 24 September 2020. The American market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
분석 기사 • Dec 15A Look At Jounce Therapeutics' (NASDAQ:JNCE) CEO RemunerationThis article will reflect on the compensation paid to Rich Murray who has served as CEO of Jounce Therapeutics, Inc...
Analyst Estimate Surprise Post Earnings • Nov 10Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 64%.
Analyst Estimate Surprise Post Earnings • Nov 08Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 64%.
Major Estimate Revision • Nov 04Analysts increase revenue estimates to US$21.9mThe 2020 consensus revenue estimate increased from US$4.17m. Earning per share (EPS) estimate also saw an improvement, with analysts raising their estimates from -US$3.09 to -US$2.62 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 7.4% next year. The consensus price target of US$13.83 was unchanged from the last update. Share price is down by 22% to US$7.02 over the past week.
Valuation Update With 7 Day Price Move • Nov 03Market pulls back on stock over the past weekAfter last week's 24% share price decline to US$6.82, the stock is trading at a trailing P/E ratio of 10.5x, down from the previous P/E ratio of 13.9x. This compares to an average P/E of 29x in the Biotechs industry in the US. Total return to shareholders over the past three years is a loss of 54%.
Price Target Changed • Sep 19Price target raised to US$14.30Up from US$10.63, the current price target is an average from 7 analysts. The new target price is 45% above the current share price of US$9.85. As of last close, the stock is up 191% over the past year.
